News

  • 14 August 2019

    Deciphera reports positive results from INVICTUS study

    Deciphera Pharmaceuticals has announced positive findings from the Phase III INVICTUS clinical trial that evaluated ripretinib for the treatment of fourth-line and fourth-line plus gastrointestinal stromal tumours (GIST).

Close
Close
Close

Go Top